Kirkland biotech Prevencio is raising a $2 million convertible note that will become part of what the company hopes will be a $20 million Series C round.
“We’ve had very strong support from our current investors, which are local angels,” said Prevencio CEO Rhonda Rhyne.
The company is holding off on raising the additional $18 million until it presents scientific data on its blood tests at a major cardiology conference later this year, Rhyne said.
The company expects that the presentation…
Kirkland biotech Prevencio is raising a $2 million convertible note that will become part of what the company hopes will be a $20 million Series C round.
“We’ve had very strong support from our current investors, which are local angels,” said Prevencio CEO Rhonda Rhyne.
The company is holding off on raising the additional $18 million until it presents scientific data on its blood tests at a major cardiology conference later this year, Rhyne said.
The company expects that the presentation…